http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2359683-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d40960190e37af1e3390c21a67554f98 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3aa24c9e809ea5e9a21a9307aac7efff http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d2536d25c606cf230e24d4f94045e92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9715ee42ca04792255166d73b4f79385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_45f2cc553ae404986e122d9dfe7e8e3e |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2008-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2009-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90fc66dba118945fc6a9be224e6b0534 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_399b6ff6dcdfa3ea70d034af657fa8f6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_730ef746b61cac8a0de3179ed98a97d0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5cf0fb0787728f30d3985a4dd2c7650b |
| publicationDate | 2009-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2359683-C1 |
| titleOfInvention | Way of treatment of refractory forms of lymphogranulomatosis |
| abstract | FIELD: medicine. n SUBSTANCE: invention concerns medicine, namely to oncology, and can be used for treatment of patients with resistant lymphogranulomatosis forms. The essence of the invention consists that a medullar suspension taken of an ileal bone of the patient is centrifugated during 30 minutes at 1500 rpm. Then the plasma is selected, divided on two parts and frozen at -40°C, corpuscles of a medullar suspension are dilluted with a sterile normal saline solution, incubated with the chemopreparations in a thermostat at 37°C during 30 minutes and reinfused to the patient intravenously driply. Further in 14 and 28 days a la carte the plasma of a medullar suspension is defrozen, diluted with a sterile normal saline solution. Every portion is incubated with the same chemopreparations in the same doses in a thermostat at temperature of 37°C during 30 minutes and reinfused to the patient intravenously driply. All complex of medical procedures is repeated in 2 weeks. n EFFECT: possibility to reach remission at patients at the expense of rising of antitumoral activityof chemopreparations at their incubation with cells of a medullar suspension and nonspecific stimulation of immunity by antigens of plasma processed with chemopreparations of a medullar suspension. n 1 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2462192-C1 |
| priorityDate | 2008-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 27.